Chemokine gene expression signatures including CCL5, CXCL9, CXCL10, and CXCL11 were reported that could accurately predict anti-PD-1 immunotherapy response for patients with head and neck squamous cell carcinoma and gastric cancer [18]. This evidence concerns the gene CCL5 and gastric cancer.